Prelude Therapeutics Incorporated financials
$3.96+1.28%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.7M | $4.6M | $5.6M | $6.5M | $0.00 | $0.00 | $4.0M | $3.0M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $5.7M | $4.6M | $5.6M | $6.5M | $0.00 | $0.00 | $4.0M | $3.0M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | — | — | 100.0% | 100.0% | — | — | — | — |
| Operating income | -$15.5M | -$14.2M | -$17.3M | -$20.4M | -$32.2M | -$34.6M | -$33.8M | -$34.4M | -$37.2M | -$34.3M | -$37.4M | -$33.4M |
| Net income | -$13.9M | -$10.4M | -$16.5M | -$19.7M | -$31.2M | -$32.1M | -$28.7M | -$32.3M | -$34.7M | -$31.4M | -$33.1M | -$30.6M |
| Net margin | −244.1% | −226.7% | −291.8% | −303.5% | — | — | −718.3% | −1075.7% | — | — | — | — |
| Diluted EPS | $-0.14 | $-0.13 | $-0.21 | $-0.26 | $-0.41 | $-0.42 | $-0.38 | $-0.43 | $-0.46 | $-0.42 | $-0.47 | $-0.45 |
| EBITDA | -$15.1M | -$13.8M | -$16.9M | -$20.0M | -$31.8M | -$34.2M | -$33.3M | -$34.0M | -$36.7M | -$33.9M | -$37.0M | -$33.1M |
| Operating cash flow | -$15.6M | -$21.7M | $23.1M | -$19.1M | -$26.1M | -$34.2M | -$20.7M | -$27.3M | -$23.1M | -$31.8M | -$23.6M | -$25.7M |
| Free cash flow | -$15.6M | -$21.7M | $23.1M | -$19.1M | -$26.1M | -$34.3M | -$20.8M | -$27.4M | -$23.4M | -$32.1M | -$24.7M | -$26.3M |
| Diluted shares | 98.4M | 82.5M | 79.7M | 76.1M | 76.0M | 76.0M | 75.9M | 75.9M | 75.8M | 75.7M | 69.8M | 67.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $26.3M | $21.8M | $35.3M | $47.5M | $25.8M | $40.3M |
| Short-term investments | $125.4M | $59.8M | $68.0M | $7.4M | $47.5M | $58.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $53.0K |
| Total assets | $189.4M | $119.6M | $141.3M | $94.8M | $114.9M | $141.3M |
| Total liabilities | $55.6M | $59.5M | $72.7M | $36.2M | $39.1M | $38.1M |
| Shareholders' equity | $133.7M | $60.2M | $68.6M | $58.5M | $75.8M | $103.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology